Table 4

Hormone therapy and asthma onset among postmenopausal women by atopic status, E3N cohort study

*Person-yearsMultivariate adjusted†Multivariate adjusted†
Non-atopic (306 cases)Atopic (251 cases)
CasesHR 95%CICasesHR 95%CI
Never use177 0291141671
Use318 4191921.04 (0.81 to 1.33)1841.52 (1.13 to 2.05)
Recency
 Recent276 5061371.02 (0.79 to 1.33)1391.52 (1.11 to 2.07)
 Past22 294411.04 (0.69 to 1.56)321.42 (0.90 to 2.25)
Duration
 <2 years104 6071231.11 (0.84 to 1.45)1101.55 (1.12 to 2.13)
 ≥2 years194 193550.88 (0.63 to 1.22)611.42 (0.98 to 2.05)
Type of treatment‡
 Oestrogen alone33 426291.43 (0.96 to 2.11)251.86 (1.18 to 2.93)
 Oestrogen/progestagens218 1391220.98 (0.75 to 1.28)1141.39 (1.01 to 1.91)
 Other47 235270.97 (0.64 to 1.47)321.76 (1.16 to 2.68)
Oestrogen route§ ‡
 Oral65 476441.19 (0.84 to 1.69)421.56 (1.05 to 2.33)
 Transdermal187 7941071.01 (0.77 to 1.33)971.43 (1.04 to 1.97)
  • * Women without any information other than age of start of menopausal hormone therapy (MHT) are excluded.

  • Ajusted for tobacco use (never smoker/current smoker/past smoker/missing information), BMI (kg/m2), ever use of oral contraceptive (yes/no), parity (nulliparous/≤2 full-term pregnancies/>2 full-term pregnancies/no information), total caloric intake (kcal/day), type of menopause (natural/surgical/unknown), further stratified by year of birth ((1925–1929)/(1930–1934)/(1935–1939)/(1940–1944)/(1945–1950)).

  • Progestagens include: progesterone, pregnane derivatives, norpregnane derivatives and testosterone derivatives. Tibolone, weak oestrogen (unopposed or not), oestrogen/testosterone, progestin only and unknown MHT.

  • § Combined or not with a progestagen. Nasal oestrogen, weak oestrogen, other hormone therapy (HT) and unknown HT not shown.